Collegium Pharmaceutical Inc. ( (COLL) ) has released its Q3 earnings. Here is a breakdown of the information Collegium Pharmaceutical Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Collegium Pharmaceutical Inc., a biopharmaceutical company, focuses on developing and commercializing innovative medications for pain management and neuropsychiatry, with a notable product, Jornay PM, for ADHD treatment.
In its third-quarter 2025 earnings report, Collegium Pharmaceutical announced record net revenue of $209.4 million, reflecting a 31% year-over-year increase. The company also raised its full-year 2025 guidance, projecting net revenue between $775 and $785 million and adjusted EBITDA between $460 and $470 million.
Key highlights include a 20% year-over-year growth in Jornay PM prescriptions, generating $41.8 million in net revenue, and a robust performance from its pain portfolio with $167.6 million in net revenue, up 11% year-over-year. The company also reported significant growth in its core products, including Belbuca, Xtampza ER, and the Nucynta Franchise.
Collegium ended the quarter with a strong cash position of $285.9 million, while continuing its strategic initiatives such as share repurchase programs and business development opportunities. The company remains focused on paying down debt and expanding its product portfolio.
Looking ahead, Collegium Pharmaceutical is committed to supporting patients with serious medical conditions and enhancing shareholder value through strategic business execution and disciplined capital management as it approaches 2026.